Targeted Quantitation of Hosst Cell Protein Impurities
Effective control of host cell protein (HCP) is crucial in biopharmaceutical production to ensure safety and regulatory compliance. Read more about KBI's use of High Resolution Mass Spectrometry for targeted quantitation of protein impurities.
KBI Biopharma Inc.
-
Country/Region:United States
-
On CPHI since:2015
-
Employees:1000 - 4999
Other Content from KBI Biopharma Inc. (11)
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force?
-
Brochure Cell Line Development, Powered by Selexis
Slow, unpredictable cell line development can cost you precious time, especially in early development, when timelines are tight and the pressure to deliver is high. KBI's Cell Line Development is made to flex, built to scale and proven to deliver. -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overview of a streamlined process for the production of bispecific molecules.
-
Brochure Cell Line Development Rebate Program
Up to $500,000 toward your first GMP batch. Discover how! -
Brochure Scale Smarter from First In Human to Market
For emerging biologics, Phase I is just the beginning. If your early data looks promising, you'll need a partner ho can handle the next steps, without forcing a complete manufacturing reset. -
Brochure Mammalian mAb Development and Manufacturing
KBI Gannt Chart - From transfection to IND ready. -
Brochure The Science is Complex. Your Manufacturing Shouldn't Be.
U.S. based data-driven centered on your molecule. KBI is your trusted partner for commercial manufacturing. -
Brochure Strategic Partnership Advances Cytotoxic ADC Manufacturing
KBI Biopharma and MilliporeSigma have partnered to provide integrated end-to-end solutions for ADCs, combining expertise in process development, mAb intermediate manufacturing, bioconjugation, and bulk drug substance production. -
Brochure SUREmAb Monoclonal Antibody Development, the Way it's Meant to Be
SUREmAb preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 18 g/L) with a streamlined, lower-cost workflow. -
Brochure Selexis TranspoEase: The Fast Track to Best-in-Class Cell Lines
KBI's cell line development - powered by Selexis TranspoEase - delivers an elite, category-setting transposase-based technology that is built on the SUREtechnology platform. -
Brochure Manufacturing Mastery: Scalable Aseptic Fill-Finish That Maximizes Yield
KBI's partner, Argonaut, can help your team manufacture with momentum across clinical and commercial phases, protecting yield and maximizing the value of every run.
Argonaut is the home for high-value drug products and complex formulations.